Aemetis Subsidiary Extends Preferred Unit Redemption and Agrees to $114.7 Million Credit Facility Terms

Reuters
Feb 07
Aemetis Subsidiary Extends Preferred Unit Redemption and Agrees to $114.7 Million Credit Facility Terms

Aemetis Biogas LLC, a subsidiary of Aemetis Inc., has amended its Series A Preferred Unit Purchase Agreement with Protair-X Technologies Inc. and Third Eye Capital Corporation. The Eleventh Waiver and Amendment, effective December 31, 2025, extends the deadline for redeeming all outstanding Series A Preferred Units to April 30, 2026, and sets the aggregate redemption price at $114.7 million, including a $2 million fee increase. If the units are not redeemed by the new deadline, Aemetis Biogas will enter into a credit agreement with Protair-X and Third Eye Capital, featuring a one-year term, an interest rate of at least 16%, guarantees from Aemetis Inc. and its subsidiaries, and a security interest in their assets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aemetis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-003382), on February 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10